Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

A. X. Zhu, R. S. Finn, P. R. Galle, J. M. Llovet, J. F. Blanc, T. Okusaka, I. Chau, D. Cella, A. Girvan, J. Gable, L. Bowman, Y. Hsu, P. B. Abada, M. Kudo

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)viii208
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this